135 related articles for article (PubMed ID: 1117072)
1. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
[TBL] [Abstract][Full Text] [Related]
2. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
[TBL] [Abstract][Full Text] [Related]
3. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
[No Abstract] [Full Text] [Related]
4. Cyanate as an inactivator of complement proteins.
Schultz DR; Arnold PI
J Immunol; 1975 Dec; 115(6):1558-65. PubMed ID: 1184967
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of C3 and factor B in patients with congenital factor I deficiency.
Rasmussen JM; Teisner B; Brandt J; Brandslund I; Gry H
J Clin Lab Immunol; 1990 Feb; 31(2):59-67. PubMed ID: 1966986
[TBL] [Abstract][Full Text] [Related]
6. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
7. Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.
Rosenfeld SI; Kelly ME; Leddy JP
J Clin Invest; 1976 Jun; 57(6):1626-34. PubMed ID: 932197
[TBL] [Abstract][Full Text] [Related]
8. Complete absence of the third component of complement in man.
Ballow M; Shira JE; Harden L; Yang SY; Day NK
J Clin Invest; 1975 Sep; 56(3):703-10. PubMed ID: 1159084
[TBL] [Abstract][Full Text] [Related]
9. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
Vogt W; Schmidt G; Lynen R; Dieminger L
J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
[TBL] [Abstract][Full Text] [Related]
10. Homozygous human C3 deficiency. The role of C3 in antibody production, C-1s-induced vasopermeability, and cobra venom-induced passive hemolysis.
Alper CA; Colten HR; Gear JS; Rabson AR; Rosen FS
J Clin Invest; 1976 Jan; 57(1):222-9. PubMed ID: 1107355
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
12. Alternative complement pathway-dependent ingestion of fluolite particles by human granulocytes.
Arnaout MA; Luscinskas FW; Lionetti FJ; Alper CA; Valeri CR
J Immunol; 1981 Jul; 127(1):278-81. PubMed ID: 6787126
[TBL] [Abstract][Full Text] [Related]
13. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
Ruddy S; Austen KF; Goetzl EJ
J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
[TBL] [Abstract][Full Text] [Related]
14. Complement activation in semi-solid medium: Insolubilization of properdin and the third component of complement (C3) in agar gels.
Ziegler JB; Watson L; Goodkofsky I; Alper CA; Lepow IH
J Immunol; 1976 Jan; 116(1):75-9. PubMed ID: 812917
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
16. Native C3 does not bind to the C3b receptor (CR1) of human blood B lymphocytes or alter immunoglobulin synthesis.
Berger M; Fleisher TA
J Immunol; 1983 Mar; 130(3):1021-3. PubMed ID: 6600466
[TBL] [Abstract][Full Text] [Related]
17. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
18. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
19. C1 inactivator and C3b inactivator in peripheral lymph of normal men.
Olszewski WL; Lukomska B; Engeset A
Arch Immunol Ther Exp (Warsz); 1982; 30(1-2):79-86. PubMed ID: 7149928
[TBL] [Abstract][Full Text] [Related]
20. The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b).
Gitlin JD; Rosen FS; Lachmann PJ
J Exp Med; 1975 May; 141(5):1221-6. PubMed ID: 1168693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
